RNAi Inhibition of Alpha-ENaC Expression
First Claim
Patent Images
1. A composition comprising an iRNA agent comprising a sense strand and an antisense strand, wherein:
- a. the sense strand comprises at least 15 contiguous nucleotides from the sense strand of ND8356 (SEQ ID NO;
143), and the antisense strand comprises at least 15 contiguous nucleotides from the antisense strand of ND8356 (SEQ ID NO;
144);
orb. the sense strand comprises at least 15 contiguous nucleotides from the sense strand of ND8379 (SEQ ID NO;
189), and the antisense strand comprises at least 15 contiguous nucleotides from the antisense strand of ND8379 (SEQ ID NO;
190);
orc. the sense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the sense strand of ND8572 (SEQ ID NO;
447), and the antisense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the antisense strand of ND8572 (SEQ ID NO;
448);
ord. the sense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the sense strand of ND8595 (SEQ ID NO;
493), and the antisense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the antisense strand of ND8595 (SEQ ID NO;
494).
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
20 Citations
21 Claims
-
1. A composition comprising an iRNA agent comprising a sense strand and an antisense strand, wherein:
-
a. the sense strand comprises at least 15 contiguous nucleotides from the sense strand of ND8356 (SEQ ID NO;
143), and the antisense strand comprises at least 15 contiguous nucleotides from the antisense strand of ND8356 (SEQ ID NO;
144);
orb. the sense strand comprises at least 15 contiguous nucleotides from the sense strand of ND8379 (SEQ ID NO;
189), and the antisense strand comprises at least 15 contiguous nucleotides from the antisense strand of ND8379 (SEQ ID NO;
190);
orc. the sense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the sense strand of ND8572 (SEQ ID NO;
447), and the antisense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the antisense strand of ND8572 (SEQ ID NO;
448);
ord. the sense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the sense strand of ND8595 (SEQ ID NO;
493), and the antisense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the antisense strand of ND8595 (SEQ ID NO;
494). - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 19, 20, 21)
-
-
17. A composition comprising an iRNA agent to alpha-ENaC, wherein the iRNA agent comprises
a sense strand and an antisense strand, wherein the sense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2, or 3 nucleotides from the sense strand of an iRNA agent selected from the group consisting of ND8356 (SEQ ID NO: - 143), ND8379 (SEQ ID NO;
189), and ND8572 (SEQ ID NO;
447), and ND8595 (SEQ ID NO;
493), andwherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2, or 3 nucleotides from the antisense strand of an iRNA agent selected from the group consisting of ND8356 (SEQ ID NO;
144), ND8379 (SEQ ID NO;
190), ND8572 (SEQ ID NO;
448), and ND8595 (SEQ ID NO;
494), the composition further comprising an epithelial receptor ligand. - View Dependent Claims (18)
- 143), ND8379 (SEQ ID NO;
Specification